Why Inghams, IAG, Neuren Pharmaceuticals, and Pro Medicus shares are sinking today

These ASX shares are ending the week deep in the red. But why?

| More on:
A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positive note. The benchmark index is currently up 0.55% to 7,647.1 points.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Inghams Group Ltd (ASX: ING)

The Inghams share price is down 13% to $3.75. Investors have been selling the poultry producer's shares despite it doubling its half-year profits. They appear to have been spooked by management's outlook commentary for the second half.

Insurance Australia Group Ltd (ASX: IAG)

The IAG share price is down 3.5% to $6.09. Although the insurance giant reported strong profit growth during the first half, it appears to have fallen short of expectations. Goldman Sachs commented: "Overall result summary: 1) Insurance profits: 1H24 result was $614m vs. GSe of $628m. 2) Cash earnings for 1H24 was $415m vs. GSe of $442m. 3) Underlying margin in line: IAG's definition of 1H24 underlying margin was 13.7% (however 15.1% ex reinsurance reinstatement) vs. GSe of 15.1%. 4) Reported margin: 1H24 reported margin was 13.7% vs. GSe of 13.9%."

Neuren Pharmaceuticals Ltd (ASX: NEU)

The Neuren Pharmaceuticals share price was down 13% to $20.04 before being paused from trade. Investors were hitting the sell button after a short seller targeted its US partner Acadia Pharmaceuticals. It alleges that the Daybue drug Neuren licensed to Acadia is a flop and that users are reporting "horror stories" from using it.

Pro Medicus Limited (ASX: PME)

The Pro Medicus share price is down 6% to $88.00. This morning, Bell Potter downgraded the health imaging technology company's shares to a sell rating with a $75.00 price target. It said: "PME remains a high quality technology group with price leadership, great margins and earnings growth through the economic cycle. Notwithstanding, the stock is overpriced relative to its peers and earnings growth and for these reasons we downgrade our recommendation to Sell."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

Three guys in shirts and ties give the thumbs down.
Share Fallers

Why Beach Energy, McMillan Shakespeare, News Corp, and Pilbara Minerals shares are falling today

These shares are ending the week in the red. But why?

Read more »

A young boy with a sombre face looks down at the zip fastener at the bottom of his jacket as he concentrates on unfastening the clasp.
BNPL shares

Should you buy the 34% dip on Zip shares?

After crashing 34% in a month, what’s next for Zip shares?

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Beach Energy, Myer, Pexa, and Pinnacle shares are falling today

These shares are under pressure on Thursday. What's going?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Block, Canyon, Fisher & Paykel Healthcare, and Mesoblast shares are falling today

These shares are having a tough time on hump day. What's going on?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Fisher & Paykel Healthcare, Magellan, Resolute Mining, and Westgold shares are sinking today

These shares are starting the week deep in the red. But why?

Read more »

plummeting gold share price
Gold

Guess which ASX 200 gold stock just plunged 12% on FY 2025 production woes

The ASX 200 gold stock is taking a sharp fall on Monday. Let’s find out why.

Read more »

Man with a hand on his head looks at a red stock market chart showing a falling share price.
Share Fallers

These were the worst performing ASX 200 shares in January 2025

These shares had a month to forget. Why were investors selling them? Let's find out.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Magellan, Medadvisor, Origin Energy, and Pointsbet shares are tumbling today

These shares are ending the week in the red. But why?

Read more »